title: 70th Birthday symposium of Prof. Dr. Riederer: autologous adult stem cells in ischemic and traumatic CNS disorders.
abstract: Ischemic and traumatic insults of the central nervous system both result in definite chronic disability, only to some extent responsive to rehabilitation. Recently, the application of autologous stem cells (fresh bone marrow-derived mononuclear cells including mesenchymal and hematopoietic stem cells) was suggested to provide a strategy to further improve neurological recovery in these disorders. During the acute phase, stem cells act mainly by neuroprotection with prevention of apoptosis, whereas during the chronic situation they provide neurorestoration by transdifferentiation and/or the secretion of neurotrophic factors. To reach these goals, in the acute phase, stem cells (10 million mononuclear cells per kg body weight) might be best applied intravenously, as during the first 7 days after the lesion, the blood-brain barrier permits passage of cells from the blood into the brain or the spinal cord. In the more chronic situation, though, those cells might be applied best intrathecally by lumbar puncture. Based on the reported results so far, it seems justified to develop well-designed clinical double-blind trials in chronic spinal cord injury and ischemic stroke patients, as efficacy and safety concerns might not be answered by preclinical studies.
authors: Amarna Therapeutics, Leiden, The Netherlands. h.demunter@hetnet.nl
authors: Johannes P J M
authors: JP
authors: de Munter
authors: Erik Ch
authors: ECh
authors: Wolters
mesh_terms: D053687:Adult Stem Cells / Q000502:physiology*; D002493:Central Nervous System Diseases / Q000209:etiology / Q000601:surgery*; D006801:Humans; D007511:Ischemia / Q000150:complications; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous